Startup profile · funding coverage
Exact Sciences funding, valuation and investors
Molecular diagnostics company behind Cologuard and broader cancer screening/therapy guidance tests.
Keep track of Exact Sciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public · Madison, WI
Overview
Exact Sciences Corp. develops and commercializes cancer screening and diagnostic tests including Cologuard. Public (NASDAQ:EXAS). SEC mailing/business address: 5505 Endeavor Lane, Madison, WI 53719. Multiple Madison campus sites including Charmany Drive manufacturing/R&D.
Why Exact Sciences is interesting
Madison’s flagship public diagnostics company (NASDAQ:EXAS) — corporate HQ 5505 Endeavor Lane, Madison, WI per SEC; major University Research Park presence.
Product & use cases
Noninvasive cancer screening and precision oncology tests sold through labs and health systems.
- At-home colorectal cancer screening
- Therapy guidance assays
- Health-system screening programs
Key facts
- NASDAQ:EXAS
- HQ: 5505 Endeavor Lane, Madison, WI 53719 (SEC)
- Flagship: Cologuard colorectal cancer screening
- Large Madison employment footprint in University Research Park
Competitive landscape
Edge: Category-defining Cologuard brand plus scaled Madison lab/manufacturing base.
-
Guardant Health adjacent
Liquid biopsy screening/therapy.
-
Freenome / other CRC screening direct
Emerging CRC screening rivals.
-
Illumina / Grail adjacency adjacent
Multi-cancer detection.
Industries
Market / IPO context
Ticker: EXAS (NASDAQ)
IPO status: public
Editorial / static context — not a live quote.
FAQs about Exact Sciences
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.